Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.
about
Synthetic Peptides as Protein MimicsConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaquesStructure-based Protocol for Identifying Mutations that Enhance Protein–Protein Binding AffinitiesCombinatorial Optimization of a CD4-Mimetic Miniprotein and Cocrystal Structures with HIV-1 gp120 Envelope GlycoproteinThe Conformation and Orientation of a 27-Residue CCR5 Peptide in a Ternary Complex with HIV-1 gp120 and a CD4-Mimic PeptideComputation-guided backbone grafting of a discontinuous motif onto a protein scaffoldStructural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5 Å Cocrystal Structure of gp120 and M48U1Interfacial Cavity Filling To Optimize CD4–Mimetic Miniprotein Interactions with HIV-1 Surface GlycoproteinAntiviral activity of animal venom peptides and related compoundsComputational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 InhibitorElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinRational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesionComputational Protein Design Through Grafting and Stabilization.Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsAnti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.Targeting protein-protein interactions for therapeutic intervention: a challenge for the future.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogensStructure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchangeBinding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection.Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.High throughput screening identifies disulfide isomerase DsbC as a very efficient partner for recombinant expression of small disulfide-rich proteins in E. coli.Direct expression and validation of phage-selected peptide variants in mammalian cells.Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimeticA tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein.Thermosensitive and mucoadhesive pluronic-hydroxypropylmethylcellulose hydrogel containing the mini-CD4 M48U1 is a promising efficient barrier against HIV diffusion through macaque cervicovaginal mucusCD4 mimetics sensitize HIV-1-infected cells to ADCC.Protein grafting of an HIV-1-inhibiting epitopeA call for replicating vector prime-protein boost strategies in HIV vaccine design.Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine designBlocking the docking of HIV-1.A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
P2860
Q26770255-E1F46B26-7CC9-480B-AC4A-29186DBF183DQ26782237-15A481FF-14CC-40CF-AECC-F2126333966BQ27339377-D7B07205-4F63-412E-B63F-89D27AC85CCFQ27646507-C3E77260-7F05-435F-AA05-D9D8D880E753Q27651139-F6622DCB-C9B3-4F47-8F2F-D9D815789F0AQ27670815-F22DC8CD-B287-4EB7-B1E0-4EDFA3680880Q27675190-398B3531-1DE9-461D-885A-8A7FEEFCE14FQ27678297-52A9681F-CFB1-43EF-92A4-EAEED7E77CA0Q27678341-93A36E1D-2123-4B87-B2EA-E00C97B07A55Q28353903-506D59F5-78A2-49EA-9E53-305EDA672DEFQ28550563-7940644A-D0C3-4135-ABC5-F0FBC2B3B53BQ28732438-8B92E0C2-64D0-4605-9838-668D1AF5AECBQ28914750-630A1CE7-BBC1-4924-80BA-E6273153EDFEQ30395950-D3C46583-BB8A-46D7-ABDC-4AC53E7F838BQ30401836-3E3A2126-3EE4-4968-A672-9745AA3D35E7Q30859838-4B968499-E55B-4332-9EF5-475A24A4A27CQ33223969-8FFF8EBD-BDC8-441D-9390-6D0A98C84C79Q33426352-82C862E4-759C-4D92-BAAF-274653EC33B2Q33780620-A188F018-549F-4867-B5B4-3E637C48C87CQ33852396-6C691373-35A1-474C-B895-0E47658E2F9FQ33946209-A332FE6F-CD27-4C5A-B906-1ED93A899C47Q33972838-B9B75E05-CC82-4AB8-BDAE-C6875630BC3FQ34055984-16471CA7-AA80-4D30-AC4F-67DC5F513DD1Q34057606-8C449CBF-E5EF-4DF7-9D4B-73778CC2D6DBQ34239109-613D76C9-57A8-4FC9-9494-817529A90F23Q34483474-00AB192B-4F07-4EFD-B17A-2FD873BF2135Q34680566-AB60B013-B52D-4A5C-8082-B82E6769112BQ34716469-6C8C0928-4C18-4B94-ACCE-1017817A3870Q35023006-E77C79E1-9F89-4FF0-82A0-0DBA2B36D0EBQ35033324-184C33B7-4439-4D24-9263-E9ED9EA355CBQ35058860-81462707-901E-41AD-958A-A26005FFF250Q35065249-2897E011-C4D5-4182-A428-D9CE4A26F34CQ35140318-4D39DE03-71D2-49CE-8770-037F156C8FC7Q35169031-DEA3219E-DF03-4FB0-9D64-FEBEAFF4C067Q35644696-DFFA42CD-4189-4772-BD78-A5580619A513Q35813478-9AD11F54-ED18-43CD-9DF2-93AC7C4B1F0BQ35851801-85A048A2-6588-4386-AEEE-A443C32CF431Q35887367-8A58C795-78E0-43AB-9C50-D44C3F8E54ACQ35976760-4DF8562D-604E-4D6C-B377-FC8556C566B6Q35978823-C8E7A80F-4F13-4C5A-9E7E-51181D022799
P2860
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@en
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@nl
type
label
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@en
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@nl
prefLabel
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@en
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@nl
P2093
P2860
P356
P1433
P1476
Rational design of a CD4 mimic ...... yptic neutralization epitopes.
@en
P2093
André Ménez
Christian Roumestand
Claudio Vita
Francesca Sironi
Francisco Veas
François Stricher
Isabelle Freulon
Loïc Martin
Martine Pugnière
Paolo Lusso
P2860
P2888
P356
10.1038/NBT768
P577
2002-12-16T00:00:00Z
P5875
P6179
1011421461